These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17698592)

  • 1. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.
    Ries M; Clarke JT; Whybra C; Mehta A; Loveday KS; Brady RO; Beck M; Schiffmann R
    J Clin Pharmacol; 2007 Oct; 47(10):1222-30. PubMed ID: 17698592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
    Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
    J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
    Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
    Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.
    Clarke JT; West ML; Bultas J; Schiffmann R
    Genet Med; 2007 Aug; 9(8):504-9. PubMed ID: 17700388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
    Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
    Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
    Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
    Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.
    Hughes DA; Deegan PB; Milligan A; Wright N; Butler LH; Jacobs A; Mehta AB
    Mol Genet Metab; 2013 Jul; 109(3):269-75. PubMed ID: 23702393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agalsidase Beta: a review of its use in the management of Fabry disease.
    Keating GM; Simpson D
    Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.